Acute Respiratory Distress Syndrome (ARDS) – Market Access and Reimbursement Insights Report – 2025

Acute Respiratory Distress Syndrome (ARDS) Market Access and Reimbursement Insights

Thelansis’s “Acute Respiratory Distress Syndrome (ARDS) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Acute Respiratory Distress Syndrome (ARDS) Overview

Acute respiratory distress syndrome (ARDS) is a catastrophic, life-threatening inflammatory lung injury characterized by the acute onset of non-cardiogenic pulmonary edema, driven by the profound disruption of the alveolar-capillary membrane barrier. This rapid increase in permeability leads to the histological hallmark of diffuse alveolar damage (DAD), hyaline membrane formation, and refractory hypoxemic respiratory failure. It manifests as a severe complication of direct pulmonary insults (such as severe pneumonia or aspiration) or indirect systemic inflammatory cascades (most notably sepsis or severe trauma). Diagnosis and severity stratification are strictly governed by the Berlin Definition, which categorizes ARDS as mild, moderate, or severe based on the degree of hypoxemia (PaO2/FiO2 ratio) in the presence of bilateral radiographic opacities not fully explained by cardiac failure or fluid overload. Because there are currently no approved targeted pharmacotherapies to halt the underlying inflammatory cascade, management is exclusively supportive. The standard of care mandates highly protocolized lung-protective mechanical ventilation—utilizing low tidal volumes and optimized positive end-expiratory pressure (PEEP) to minimize ventilator-induced lung injury (VILI)—alongside conservative fluid management. For patients with severe, refractory hypoxemia, modern critical care relies heavily on advanced rescue interventions, including early extended prone positioning, neuromuscular blockade, and venovenous extracorporeal membrane oxygenation (VV-ECMO).

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Acute Respiratory Distress Syndrome (ARDS) – Market Access and Reimbursement Insights Report – 2025